Beijing-based biotech firm Isap Biotech has announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its injectable agent, iSAP-0909. The agent will be assessed for its use in the auxiliary diagnosis and intraoperative localization of non-muscle invasive bladder cancer (NMIBC).
iSAP-0909: A Next-Generation Nanofluorescence Imaging Agent
iSAP-0909 is a next-generation pan tumor nanofluorescence imaging agent developed independently by Isap Bio, utilizing “in situ self-assembly” nanobiotechnology. This agent is characterized by high sensitivity, high specificity, and long-term stable high brightness, which enables the identification of small lesions and metastases. It is designed to reduce false positives caused by inflammation and is expected to enhance the accuracy of intraoperative navigation during surgical procedures for cancer patients.- Flcube.com
